-
Mashup Score: 55No excess long‐term mortality in stage I‐IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy - 4 month(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma - 6 month(s) ago
Key Points. A considerable subset of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma.Assessment of T-cell clonality c
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Overall survival of cHL patients who progress after autologous stem cell transplant: results in novel agent era. - 6 month(s) ago
Key Points. Overall survival of cHL patients who progress after autologous stem cell transplant approached 9.5 years in novel agent era.Patients who receive CPI
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Lisa Roth, MD, Weill Cornell Medicine, New York, NY, discusses a multicenter retrospective study of pediatric patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) who received brentuximab vedotin (BV) as maintenance therapy following autologous stem cell transplantation (autoSCT). Dr Roth shares that the treatment was well tolerated and safe, suggesting that this agent may be a promising option for pediatric patients. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Currently, there is no standard of care for older patients who develop classical Hodgkin lymphoma (cHL), and conventional chemotherapy is associated with several toxicities. In this video, Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, shares some insights into a study evaluating the safety and efficacy of pembrolizumab monotherapy in patients with cHL ineligible for frontline ABVD. Prof. Dickinson discusses the inclusion criteria for this trial, and further summarizes the results, including the progression-free and overall survival (PFS; OS) rates observed. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Interim PET-Guided Treatment for Early-Stage NLPHL | ASH Clinical News | American Society of Hematology - 8 month(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago. To achieve optimal disease control in patients with early-stage favorable nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), consolidation radiotherapy (RT) appears necessary after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemot herapy, irrespective of the interim positron emission tomography (iPET) result, concluded Dennis Eichenauer, MD, of the University of Cologne in Germany, and colleagues in a
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
David Bond, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, discusses the results of a Phase I/II study…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 10Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma - 9 month(s) ago
Key Points. One hundred percent of patients remain alive without relapse following sequential pembrolizumab and AVD after nearly 3 years of follow-up.PD-1 pathw
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0AVENuE window study: avelumab monotherapy followed by PET-adapted chemotherapy approach in cHL - 9 month(s) ago
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares some insights into the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Concurrent Pembrolizumab and AVD as Frontline Therapy in Untreated cHL | ASH Clinical News | American Society of Hematology - 10 month(s) ago
Skip Nav Destination June 1, 2023 Katie Robinson is a freelance medical writer based in New York. In patients with untreated classical Hodgkin lymphoma (cHL), concurrent use of pembrolizumab and the chemotherapy combination of…
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The thesis of Ingemar Lagerlof in 4 tweets. Paper 1: #Hodgkin early stage pts 1999-2005, ABVD + limited field RT. Rel survival equal to gen population. Great news for pts. 1 subgroup did worse: early PD. Need to maintain focus on disease control. https://t.co/8dGgcuuzBG